Suzanne Louise Bruhn - Aug 11, 2022 Form 4 Insider Report for Mind Medicine (MindMed) Inc. (MNMD)

Role
Director
Signature
/s/ Carrie Liao, Attorney-in-Fact
Stock symbol
MNMD
Transactions as of
Aug 11, 2022
Transactions value $
$0
Form type
4
Date filed
8/15/2022, 09:55 PM
Previous filing
Jul 28, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNMD Common Shares Award $0 +89.3K $0.00 89.3K Aug 11, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNMD Stock Option (Right to Buy) Award $0 +121K $0.00 121K Aug 11, 2022 Common Shares 121K $0.66 Direct F2, F3
transaction MNMD Director's Deferred Share Units Award +504K 504K Aug 11, 2022 Common Shares Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. These RSUs will vest in three equal annual installments over such three-year period; provided, that in the event that the Reporting Person's continuous service as a member of the Board terminates for any reason other than for cause after the first anniversary of the grant date, a portion of these RSUs that would have vested on the next annual vesting date following the date of departure will immediately vest in full as of the date of termination of service on a prorated basis.
F2 The option grant has an exercise price of $0.84 Canadian Dollars. This represents the exercise price in United States Dollars.
F3 The shares underlying the option shall vest and become exercisable 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F4 Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan).